Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 10 | 7 | 2 | — | — | 13 |
Plasma cell neoplasms | D054219 | — | — | 10 | 7 | 2 | — | — | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | 1 | 6 |
Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Drug common name | Mezigdomide |
INN | mezigdomide |
Description | Mezigdomide is a cereblon E3 ligase modulator developed by Bristol Myers Squibb to treat multiple myeloma.
|
Classification | Small molecule |
Drug class | thalidomide derivatives: zinc finger protein degradation inducing thalidomide derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccc(N2CCN(Cc3ccc(COc4cccc5c4CN([C@H]4CCC(=O)NC4=O)C5=O)cc3)CC2)c(F)c1 |
PDB | — |
CAS-ID | 2259648-80-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4648616 |
ChEBI ID | — |
PubChem CID | 137379043 |
DrugBank | — |
UNII ID | LA88IH4O02 (ChemIDplus, GSRS) |